Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Liabilities and Shareholders Equity (2022 - 2025)

CervoMed (CRVO) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $22.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 46.89% to $22.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $130.1 million through Dec 2025, down 15.02% year-over-year, with the annual reading at $22.9 million for FY2025, 46.89% down from the prior year.
  • Liabilities and Shareholders Equity hit $22.9 million in Q4 2025 for CervoMed, down from $30.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $53.2 million in Q2 2024 to a low of $3.4 million in Q2 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $25.4 million across 4 years, with a median of $27.8 million in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 88.47% in 2023 and later soared 1481.07% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $4.2 million in 2022, then skyrocketed by 139.86% to $10.0 million in 2023, then soared by 332.0% to $43.1 million in 2024, then crashed by 46.89% to $22.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CRVO at $22.9 million in Q4 2025, $30.6 million in Q3 2025, and $38.1 million in Q2 2025.